Correspondence 0001493152-24-026323 from Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc.
Date: July 5, 2024 · CIK: 0001708599 · Accession: 0001493152-24-026323
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279121
Letter
Serina Therapeutics, Inc.
Genome Way
Suite
Huntsville, Alabama 35806
(256) 327-9630
July 5, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, NE
Washington, D.C. 20549
Attention: Tim Buchmiller and Lauren Hamill
Re: Serina Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-279121
Ladies and Gentlemen;
In accordance with Rule 461 under the Securities Act of 1933, as amended, Serina Therapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Tuesday, July 9, 2024, or as soon thereafter as is practicable.
Please contact Stephen Hinton of Bradley Arant Boult Cummings LLP, the Company’s legal counsel, at (205) 521-8406, if you have any questions or concerns regarding this matter. Thank you in advance for your assistance.
Sincerely,
SERINA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Serina
Therapeutics, Inc.
601
Genome Way
Suite
2001
Huntsville,
Alabama 35806
(256)
327-9630
July
5, 2024
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, NE
Washington,
D.C. 20549
Attention:
Tim Buchmiller and Lauren Hamill
Re:
Serina Therapeutics, Inc.
Registration
Statement on Form S-1
File
No. 333-279121
Ladies
and Gentlemen;
In
accordance with Rule 461 under the Securities Act of 1933, as amended, Serina Therapeutics, Inc., a Delaware corporation (the “Company”),
respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared
effective at 4:00 p.m., Eastern Time, on Tuesday, July 9, 2024, or as soon thereafter as is practicable.
Please
contact Stephen Hinton of Bradley Arant Boult Cummings LLP, the Company’s legal counsel, at (205) 521-8406, if you have any questions
or concerns regarding this matter. Thank you in advance for your assistance.
Sincerely,
SERINA THERAPEUTICS, INC.
By:
/s/ Andrea Park
Name:
Andrea Park
Title:
Interim Chief Financial Officer and Chief Accounting Officer
cc:
Stephen Hinton, Bradley Arant Boult Cummings LLP